x

Thumbs upLive

Clients are currently raving about this firm’s Billing Transparency in Corporate/Commercial

View Firm Profile

Life sciences and healthcare in London

Allen & Overy LLP

Allen & Overy LLP’s UK-based practice is jointly led by global co-head of life sciences Jim Ford and head of the healthcare transactions team Matthew Appleton. The department’s multi-disciplinary approach allows for expertise across M&A, commercial issues, IP mandates, financing work and regulatory matters as well as dispute resolution. The group counts leading pharmaceuticals companies, biotech businesses and medical device manufacturers on its client roster, as well as names involved in the vaccination, healthcare, consumer and veterinary sectors. Other key individuals include ‘stand-out partnersMarjan Noor and Rafi Allos, who are both IP litigators and ‘experienced experts who are easy to deal with and provide a great client service’; Allos was promoted to the partnership in 2022.

Responsables de la pratique:

Jim Ford; Matthew Appleton

Autres avocats clés:

Marjan Noor; Rafi Allos; Mark Ridgway; Neville Cordell

Les références

‘Marjan Noor and Rafi Allos are the stand out partners on this practice area. Experienced experts who are easy to deal with and provide a great client service.’

‘A&O life sciences team is excellent and goes hand in hand with the IP litigation team who have excellent life sciences team. In addition, there are regulatory law capabilities which span across Europe. Overall great compliment to IP litigation team.’

‘Marjan Noor is an excellent litigator in the life sciences space with great knowledge of the SPC law as well. She is happy to get into the nitty gritty detail and takes a very hands-on approach. Excellent partner to work with. Rafi Allos is a recently promoted partner focusing on the regulatory side as well as patent litigation. Rafi’s knowledge of regulatory law is excellent and a partner to look out for in the future.’

Principaux clients

Exscientia

GlaxoSmithKline

Abdul Latif Jameel Health

Babylon Health

MGI Tech

Principaux dossiers

  • Advised Exscientia on its $5.2bn strategic research collaboration with Sanofi to develop an AI-driven pipeline of precision-engineered medicines.
  • Advised GSK on its strategic collaboration with German biotech company CureVac for the research, development and commercialisation of mRNA-based vaccines and monoclonal antibodies targeting infectious diseases.
  • Represented MGI Tech in patent infringement and revocation proceedings relating to five patents in the UK, which involved defending an injunction application and an expedited trial.

Bird & Bird LLP

With ‘unparalleled depth of industry knowledge’ and a ‘dynamic team’, Bird & Bird LLP is ‘always focused on the client’s needs and strives to deliver solution-oriented, valuable advice’. Excelling across the full spectrum of life sciences work, the group is particularly lauded for its expertise in pharmaceutical and life sciences patent litigation; in a recent highlight, the team acted for Gilead in patent revocation and infringement proceedings relating to its range of anti-viral blockbuster products containing sofosbuvir. The group counts high-profile pharmaceutical, biotech and medical devices companies on its client roster and leverages the firm’s international network, including the recently established Irish office, to assist at a global level. Mark Hilton and Sally Shorthose jointly lead the department, which also fields corporate specialist James Baillieu and recently promoted partner Chris De Mauny.

Responsables de la pratique:

Mark Hilton; Sally Shorthose

Autres avocats clés:

James Baillieu; Chris De Mauny

Les références

‘Scope of technical backgrounds. Enjoyable and committed lawyers.’

‘The team appears very knowledgeable about our industries, takes very little time to get onboarded and is highly qualified. Also appreciate that they think along in terms of cost efficiencies and required expertise.’

‘Partner James Baillieu is my main contact person. Always on the ball, pragmatic, doesn’t over complicate matters and very good at translating complex legal matters to business people.’

‘The Bird & Bird team convinces with their global footprint, their very strong analytical skills, well-grounded legal analysis of complex legal issues. The team is always focused on the client´s needs and strives to deliver solution-oriented valuable advice.’

‘Excellent knowledge and good strategic advice. Good team dynamic’

‘Unparalleled depth of industry knowledge.’

‘Mark Hilton has a truly valuable understanding of the life sciences industry and this cascades down through the team.’

Principaux clients

Dexcom

Gilead

Teva

The Broad Institute

Merck KGaA

UK Global Healthcare Ltd

Precision Medicine

Omnicell

Serum Institute of India

Polpharma

Fisher & Paykel Healthcare

Amgen

Sanofi

Principaux dossiers

  • Acting for Gilead in patent revocation and infringement proceedings in the UK which concern Gilead’s range of anti-viral blockbuster products containing the drug sofosbuvir.
  • Successfully represented Polpharma in a judicial review at the EU General Court in relation to the regulatory data protection (RDP – data exclusivity) of Tecfidera.
  • Advised Korean-based Mirae Asset Capital, Celltrion and Premier Partners on Iksuda Therapeutics Limited’s $47m Series A financing.

Bristows LLP

Bristows LLP is ‘widely respected throughout Europe for coordinating multi-jurisdictional disputes’ and has ‘a justified reputation as one of the leading firms for IP life sciences work’. Jointly led by ‘commercially savvy’ patent litigator Liz Cohen and transactional specialist Richard Dickinson, the practice covers all facets of IP, transactional, regulatory and contentious work, regularly acting for high-profile clients including GlaxoSmithKline, Novartis, Teva and the University of Oxford. On the patent litigation front, other key names include Brian Cordery, the ‘technically brilliantRobert Burrows and Dominic Adair, while key contacts for transactional work include Marek Petecki and Claire Smith. Matthew Warren excels at commercial mandates and Alex Denoon leads the regulatory practice.

Responsables de la pratique:

Liz Cohen; Richard Dickinson

Autres avocats clés:

Brian Cordery; Robert Burrows; Dominic Adair; Marek Petecki; Claire Smith; Matthew Warren; Alex Denoon

Les références

‘Justified reputation as one of, if not the, leading firms for IP life sciences. Excellent reputation in the UK and beyond – widely respected throughout Europe for coordinating multi-jurisdictional disputes.’

‘Brian Cordery – Quite simply the leading solicitor in the UK for pharmaceutical litigation.’

‘Liz Cohen – Excellent litigator, commercially savvy, great team leader/management, unflappable and charming.’

‘Rob Burrows – Excellent litigator, technically brilliant.’

‘The team has exceptional knowledge of the life sciences space. It acts for a broad range of industry players and has a deep understanding of market practice. It is credible with the big pharma companies we deal with.’

‘Matthew Warren leads the team we work with. Matthew is thorough and dependable. He is generally available which is helpful. Matthew has worked on most of the innovative projects we have undertaken in the last few years.’

‘The Bristows team members are not only exceptionally good at a professional level, but, at the same time, very easy to talk to and discuss with. They always have an open ear for the client’s needs and are happy to brainstorm.’

‘Not only is Bristows’ advice first rate (technically and commercially), but the teams are a pleasure to work with and they are continually making my life easier as the client. They have a team of amazing professionals and are constantly looking for new ways to provide the best service for their clients – whether it is staffing, billing, information sharing etc.’

Principaux clients

Novartis

Teva

Johnson & Johnson

AstraZeneca

Genomics England

Sensyne Health

Smith + Nephew

GlaxoSmithKline

University of Oxford

Fresenius Kabi Deutschland GmBH

Principaux dossiers

  • Handled a Series A financing round for AviadoBio Limited.

CMS

Fielding ‘true specialists in life sciences and healthcare’, CMS is ‘rightly considered to be one of the elite practices in this area’. The group is equally adept across both the life sciences and healthcare arenas, covering corporate and real estate transactions, financing work, IP mandates, regulatory issues and litigation for a client roster of pharmaceutical companies, medical device companies, healthcare providers and biotech businesses. Sarah Hanson, Robert Stephen and Candice Blackwood jointly lead the practice; Hanson specialises in commercial, IP and outsourcing transactions, Stephen is a highly experienced patent litigator, and Blackwood (who leads the healthcare group) focuses on real estate mandates. Shuna Mason is also recommended for regulatory and product liability work; Mark Shillito, who joined from Herbert Smith Freehills LLP in 2022, handles patent litigation; and Rachel Cooper regularly acts for healthcare clients on regulatory matters.

Responsables de la pratique:

Sarah Hanson; Robert Stephen; Candice Blackwood

Autres avocats clés:

Shuna Mason; Mark Shillito; Rachel Cooper; Elizabeth-Anne Larsen

Les références

‘They are true specialists in life sciences and healthcare – equally at home in advising on regulatory compliance as well as disputes. They have international outlook and reach – with a loyal client base who recognise their ability to provide both strategic advice and representation in the different areas of the world. The practice is growing from strength to strength in recent years – and is rightly considered to be one of the elite practices in this area.’

‘Shuna Mason is the grande dame of this practice area. She has decades of experience in advising corporate clients through the minefield that is healthcare regulation, and is a seasoned litigator with an amazing pedigree in the high octane world of group litigation. She works tirelessly for clients – always with a bright and positive outlook. And you know that her judgement is always spot on because it has been honed years of experience.’

‘Elizabeth-Anne Larsen is a rising star in the field. She has an impressive and varied caseload – from high-profile group litigation, to unitary clinical negligence claims, to disciplinary matters. She is a real stakhanovite – but however hard she works, there is always a smile on her face.’

‘The CMS life sciences group have extensive experience in all the critical aspects of life sciences whether it be corporate, M&A, licensing, IP. They are truly full service. No matter the problem, they work with me to find a solution. They are also super attentive, which I very much appreciate. And, most importantly they just do great work.’

‘CMS team provided support in data protection legal compliance work in relation to human research/clinical studies. The job requires cross-functional knowledge in Data Protection and Life science and CMS were able to provide such resource. Where any follow up work was needed after a period of time, they could manage continuity even in case of change in key advising lawyer. They are able to advise on multiple jurisdictions and bring practical recommendations in conversations even in challenging matters.’

Principaux clients

Eli Lilly

Amicus

Care UK

Contura Holdings

Essential Pharma

GlaxoSmithKline

HCA International

Johnson & Johnson

Korian S.A

Medtronic

Moorfields Eye Hospital NHS Trust and UCL London

Nestlé

Nuffield Health

Sanofi

Spire Healthcare

Teva

The Wellcome Trust

Thermo Fisher Scientific

UK Health Security Agency

Welltower Inc

Principaux dossiers

  • Advising Essential Pharma on a suite of novel and complex agreements relating to the purchase of the rights to a number of niche products from, and the disposal of the rights to a suite of oral liquid products to, Rosemont Pharmaceuticals.
  • Advising Moorfields NHS Trust and University College London on all real estate, development, planning, rights of light, procurement, and construction matters as well as the joint venture delivery vehicle for the £500m Project Oriel – the building of a new, world leading eye care and research centre in central London.
  • Advising Alliance Pharma PLC on its appeal to the Competition Appeal Tribunal, following the CMA’s enforcement decision in its investigation into the supply of Prochlorperazine, a medication used for treating nausea.

Herbert Smith Freehills LLP

Herbert Smith Freehills LLP’s ‘commercial, pragmatic and responsive’ team is a key name in the market for high-profile clients spanning pharmaceutical companies, generics players, medtech businesses and investors. Alan Montgomery heads up the practice and is also co-head of the global pharmaceuticals team; he specialises in transactional work and commercial mandates. Other key individuals include patent litigators Sebastian Moore (who divides his time between London and Milan) and Sophie Rich, and Jonathan Turnbull, who assists R&D pharmaceutical companies with commercial matters. The team is notably active in defending clients against biosimilar challenges and also handles innovative mandates relating to companion diagnostics and personalised medicine.

Responsables de la pratique:

Alan Montgomery

Autres avocats clés:

Sebastian Moore; Sophie Rich; Jonathan Turnbull

Les références

‘Ability to effectively work across multiple disciplines seamlessly.’

‘Commercial, pragmatic and responsive.’

‘Sebastian Moore is an outstanding practitioner. He is smart, practical, and caring. He is also an excellent team leader.’

‘Knowledgeable and well-experienced in managing complex and cross-jurisdictional matters and litigation in the life sciences and healthcare space.’

‘Very responsive and collaborative mindset.’

‘”All clients first”, this is what makes the difference. A large international brand that still keeps the advantages of a boutique firm where clients are really and truly cared for.’

Principaux clients

Gilead Sciences, Inc

Johnson Matthey

Biotage AB

Abcam Plc

Genus Plc

Acacia Research Corporation

Takeda / Millennium Pharmaceuticals

Foundation Medicine Inc

Vimian Group

Asklepios Biopharmaceutical, Inc.

Principaux dossiers

  • Advised Gilead Sciences in UK patent proceedings relating to Gilead’s HIV integrase inhibitor, bictegravir, which forms part of Gilead’s blockbuster anti-HIV regimen BIKTARVY.
  • Advised Johnson Matthey on the £325m sale of its Health business to Altaris Capital Partners.
  • Advised Foundation Medicine Inc. (a subsidiary of leading Swiss multinational healthcare company, Roche) in preparing for, and then initiating and defending, European proceedings in relation to a large number of a key competitor’s IP rights.

Hogan Lovells International LLP

Hogan Lovells International LLP fields a ‘very strong, stable and clever team’, which has ‘synergy that harnesses the individual strengths of the team and promotes highly efficient practices’ during the group’s work on high-profile multi-disciplinary and multi-jurisdictional matters. At the helm, Stephen Bennett and Matthew Felwick co-chair the London life sciences and healthcare practice, while Jane Summerfield leads the UK life sciences and healthcare regulatory and commercial practice and is also co-head of the firm’s global sector group. Bennett focuses on patent litigation, Felwick is a key name for product and commercial litigation, and Summerfield specialises in regulatory mandates, while newly promoted partner Penny Powell is the primary name for transactional work and counsel Elise Martin is active in product safety issues and compliance work.

Responsables de la pratique:

Stephen Bennett; Matthew Felwick; Jane Summerfield

Autres avocats clés:

Penny Powell; Elise Martin

Les références

‘Jane Summerfield at Hogan Lovells has been a fantastic part of our working group to help our business succeed.’

‘The Hogan Lovells Team offers world-class data protection advice thanks to their in-depth knowledge of the life sciences and healthcare industry, understanding of regulators’ expectations and ability to anticipate legal trends. The team is very friendly and approachable and most importantly able to provide pragmatic solutions to very complex issues.’

‘Strong core knowledge of their area, both the law and the underlying scientific background, fortified by the involvement of specialist scientists. A team whose synergy harnesses the individual strengths of the team and promotes highly efficient practices.’

‘A very strong, stable, clever team.’

‘Stephen Bennett and others form a very bright, innovative, client-friendly team. Many brains and huge experience.’

‘Good knowledge of life science.’

Principaux clients

Novartis Pharma AG

Bristol Myers Squibb

Merck Sharp and Dohme

Zimmer Biomet

Astellas Pharmaceuticals

Sandoz AG

AmerisourceBergen Corporation

Akebia Therapeutics

Cardiorentis

Principaux dossiers

  • Advising Novartis Pharma AG’s Biotechnology & CMO division in relation to agreements relating to the clinical production and release of mRNAs to be used to develop a Seasonal Influenza Vaccine and GSK’s omicron Covid Vaccine.
  • Representing Bristol Myers Squibb in its dispute over the patents protecting apixaban – a blockbuster drug for treatment of thromboembolic disorders.
  • Acting for Zimmer Biomet and various European subsidiaries in relation to personal injury claims concerning Biomet’s metal-on-metal prosthetic hip replacements.

Pinsent Masons LLP

As ‘a real stand-out firm in the life sciences and pharmaceutical sectors’, Pinsent Masons LLP fields distinct life sciences and healthcare teams led by Clare Tunstall and Joanne Ellis respectively. On the life sciences front, the substantial team was further strengthened through the recruitment of Gareth Morgan and his team from CMS, adding to the existing IP capabilities covered by Tunstall and Charlotte Weekes. The group also excels in multijurisdictional litigation, high-profile transactions and regulatory mandates, with Allistair Booth handling licensing and collaboration matters and other transactional work and Charles Waddell assisting with biotech and medtech financings. For healthcare clients, the practice is active across the sector, acting on PPP and PFI hospitals, joint ventures and investment mandates; the team has also developed a niche in dental M&A.

Responsables de la pratique:

Clare Tunstall; Joanne Ellis

Autres avocats clés:

Gareth Morgan; Charlotte Weekes; Allistair Booth; Charles Waddell; Chris Sharp; Catherine Drew

Les références

‘Pinsent Masons is a real stand out firm in the life sciences and pharmaceutical sector. They have huge experience in this sector and understand both the legal and commercial landscape allowing them to provide truly excellent and well rounded advice.’

‘Chris Sharp and Charlotte Weekes are stand out litigators in this sector. Chris is involved in a huge number of cases in the Courts at the moment and is one of the current stars of the UK pharmaceutical patent scene. Charlotte Weekes provides thoughtful, directed advice for clients and has a real understanding of the industry and what matters in litigation and the best strategies to employ.’

‘PM’s life sciences practice has great breadth and depth. It has many individuals with detailed industry knowledge and expertise across a wide range of practice areas.’

‘Gareth Morgan and Catherine Drew are stand out partners for regulatory life sciences advisory and contentious work. They stand out for their experience and expertise in this specialist area which few others in the UK can legitimately claim to have. Both are easy to work with and give practical, clear and business focused advice.’

Principaux clients

Her Majesty’s Government

Sandoz

Teva Pharmaceutical Industries Limited

Accord Healthcare Limited

4D Pharma PLC

IP Group PLC

C4X Discovery PLC

Sun Pharma

Flynn Pharma Limited

Porton Biopharma

Amo Pharma Limited

ANGLE plc

Basics GmbH

BGMA – British Generic Manufacturers Association

BioEq AG

Calon Cardio-Technology

Cosmo Pharmaceuticals NV

Crescent Pharma

DCC Healthcare

Evgen PLC

F2G Limited

Genesis Biosciences Inc

HC-One

Hikma

IBSA Institut Biochimique

Imcyse S.A.

Intas Pharmaceuticals

JUUL Labs Inc

Karus Therapeutics Limited

LIDCO Group

Medherant

Medray

MfE – Medicines for Europe

Neuro-Bio

Oribiotech Limited

Oxford Genetics Limited

RedX Pharma PLC

University of Edinburgh

Vertex

Zentiva Group a.s

Department for Business, Energy and Industrials Strategy and the Department of Health and Social Care

Erisbeg Holdings Limited

Kingdom Holding Group Limited

McCarthy & Stone Retirement Lifestyles Limited

Partou Kids Foundation

Retirement Villages Group (RVG) (AXA owned)

Riverdale

The shareholders of Kids Planet Day Nurseries Limited

Twenty20 Capital

UCL (University College London)

UDG Healthcare

Principaux dossiers

  • Advised various UK Government Departments on Covid related projects of national importance such as (i) the acquisition of vaccines for use in the booster programme and specialist Covid Antivirals; (ii) advising on cutting edge clinical trials and (iii) vaccine swaps involving a number of countries around the world.
  • Advised Flynn Pharma on ground-breaking patent and competition law issues in actions relating to Circadin, cases which changed the landscape for preliminary injunctions in the UK and involved the first alleged competition law abuse of a divisional patent strategy.
  • Advised C4X Discovery Holdings on its €414m transformative global licensing deal with Sanofi for its oral pre-clinical IL-17 antibody inhibitor.

Arnold & Porter

Arnold & Porter is a go-to name in the market for regulatory and product liability mandates, and has also been notably active in matters relating to the Covid-19 pandemic and the related vaccines, counting Pfizer, AstraZeneca and Takeda on its client roster. The group has also developed niche expertise in the cannabis market, handling venture capital and M&A work. Adela Williams leads the department and advises clients on the regulation of medicinal products and medical devices at a national and EU level. Other key individuals include senior counsel Ian Dodds-Smith, Jacqueline Mulryne, patent litigator Beatriz San Martin and commercial specialist Ewan Townsend.

Responsables de la pratique:

Adela Williams

Autres avocats clés:

Ian Dodds-Smith; Jacqueline Mulryne; Beatriz San Martin; Ewan Townsend

Principaux clients

Bayer

Pfizer

Grünenthal GmbH

Orion Inc

Santen Pharmaceuticals

Norgine

AstraZeneca

Bristol-Myers Squibb

Boston Scientific

Roche Diagnostics Limited

Sanofi

Bausch

Janssen

Kyowa Kirin

Takeda

Baker McKenzie

Under the joint leadership of Hiroshi Sheraton and Jane Hobson, Baker McKenzie’s healthcare and life sciences practice takes an integrated cross-departmental approach to the full range of transactional, IP, regulatory and contentious work; it is particularly praised for its compliance and investigations team, transactional group and regulatory work. Within the practice, Sheraton focuses on patent and trade mark work, while Hobson handles corporate mandates; the group also has commercial and public procurement expertise, data privacy knowledge and experience handling matters arising from the global Covid-19 pandemic.

Responsables de la pratique:

Hiroshi Sheraton; Jane Hobson

Principaux dossiers

  • Advised Lyra Health on its acquisition of ICAS World, a global employee-assistance program provider with care professionals who support people in more than 155 countries and 66 languages.

Clifford Chance LLP

Clifford Chance LLP’s healthcare and life sciences group is praised by clients for its ability to ‘hit the ground running at full tilt in order to navigate strategic and commercial issues against incredibly tight time frames’. With notable experience acting for biotech, pharmaceutical, medical device and healthcare companies, the team leverages the firm’s wider network to advise on a range of global mandates spanning the entire product lifecycle. The practice is also recognised for its expertise in the health tech arena and the cannabis-based therapeutic market. Stephen Reese and Gareth Camp jointly lead the group, specialising in IP and corporate work, respectively.

Responsables de la pratique:

Stephen Reese; Gareth Camp

Les références

‘Clifford Chance responded with equal urgency and relevance. the team’s knowledge of the sector and its key players was invaluable and meant that we hit the ground running at full tilt in order to navigate strategic and commercial issues against incredibly tight time frames. availability was never an issue and, of real importance to me, was the way that Clifford integrated fully into the team and established rapport and transparency in the working relationship.’

‘I had the pleasure of working with Stephen Reese and his team on a couple of critical projects during the Covid crisis. The level of support they were able to provide to myself as the accountable project lead was first class. I particularly appreciated their astute insights into potential strategies in what was an extremely fluid, globally competitive and politically intense environment. I also hugely appreciated the way they supported my need to not take any possibility off the table in search of breakthroughs.’

‘Excellent sector knowledge.’

‘Stephen Reese has excellent sector knowledge and delivers to the brief perfectly.’

Principaux clients

Pfizer Inc

Her Majesty’s Government

Gyrus Capital

Moorfields Eye Hospital NHS Trust

AGC Biologics A/S

Quell Therapeutics

Moorfields Eye Hospital NHS Trust

Cinven

Fujifilm Kyowa Kirin Biologics

Principaux dossiers

  • Advising Pfizer on its global patent licensing and collaboration agreement with BioNTech for the development and commercialisation of the world’s first approved Covid-19 vaccine.
  • Advising the UK Vaccine Taskforce on behalf of Her Majesty’s Government on the IP licensing, development, manufacturing and supply of multiple vaccines to the UK population for the treatment of Covid-19.
  • Representing Pfizer before the Court of Appeal in the ongoing phenytoin case.

Cooley (UK) LLP

With ‘deep expertise in the sector’, Cooley (UK) LLP is highly regarded in the life sciences space for its corporate and commercial expertise, regularly acting for clients on M&A transactions, funding issues, IPOs, licensing work and collaboration agreements. The practice takes the active decision to not advise ‘big pharma’ companies, instead focusing on biotech and specialty pharmaceutical clients and innovators in the life sciences sector. Nicola Maguire and John Wilkinson jointly head up the group, which benefits from the firm’s close ties to its US network, including leveraging the expertise of several London-based US-qualified practitioners. Frances Stocks Allen joined the team from Latham & Watkins in 2022.

Responsables de la pratique:

Nicola Maguire; John Wilkinson

Autres avocats clés:

Frances Stocks Allen

Les références

‘I have been very impressed with the team, which is UK based with US expertise which works very well for European clients – being in the same time zone saves a lot of time. I am happy with the cross-functionality and feel like the firm gives us full back-up even if we are a new client.’

‘Deep expertise in this sector, understand the unique issues and excellent knowledge of current market practice.’

‘Excellent team with good understanding of life sciences.’

‘Nicola Maguire and her team have the perfect balance of broad experience and specialist knowledge of the life sciences industry.’

Principaux clients

AgomAb Therapeutics

Alvotech Holdings

Apollo Therapeutics

Artios Pharma

Baylis Medical Company Inc

Biote

BitBio

CEPI (Coalition for Epidemic Preparedness Innovations)

Dunad Therapeutics

Exscientia

Immunocore plc

PhaseBio Pharmaceuticals, Inc.

Quell Therapeutics

Silence Therapeutics plc

Union Therapeutics

Valneva SE

VaxEquity

ZOLL Medical Corporation

Principaux dossiers

  • Advised CEPI on its partnership with VBI Vaccines Inc. to develop VBI’s vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant.
  • Advised Dunad Therapeutics on its strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs.
  • Advised PhaseBio Pharmaceuticals on its exclusive licensing agreement and supply agreement with Alfasigma S.p.A.

Gowling WLG

Gowling WLG’s cross-departmental life sciences sector group handles the full spectrum of life sciences work encompassing transactions, patent disputes, regulatory issues and commercial work. The team counts several high-profile pharmaceutical companies on its client roster, including AstraZeneca and BioNTech. The firm also fields a distinct health and care team, which acts for a range of health and care service providers and investors, and is highly regarded for its real estate work relating to care homes and senior living facilities. Patrick Duxbury and Robert Breedon lead the group; Duxbury focuses on life sciences transactions and Breedon handles corporate work in the health and care sectors.

Responsables de la pratique:

Patrick Duxbury; Robert Breedon

Principaux clients

BioNTech

Gyrus Captial

Beckman Coulter

Neurim Pharmaceuticals

AstraZeneca

Eisai

Bial Portela

Katholike Universiteit Leuven

Dynavax

Argenx NV

BioInvent International AB

GSK

Apposite Capital

Sosei Heptares

Amphista Therapeutics

Birmingham Women’s and Children’s Hospitals NHS Foundation Trust

UDG Healthcare Group plc

Circle Health

Department of Health and Social Care

Ford

Formation Capital, LLC

Fresenius Medical Care Renal Services Limited

Getinge Group

Guy’s & St Thomas’ NHS Foundation Trust

Synlab Group

Lakeside Healthcare

Montreux Healthcare Fixed Yield Fund (inc. Huntercombe Group)

TT Electronics

Oxford University Hospitals NHS Foundation Trust

Sitekit Applications Limited

NHS Birmingham and Solihull Mental Health NHS Foundation Trust

Principaux dossiers

  • Advised BioNTech on a new research, development and commercialisation collaboration with Pfizer to develop a potential first mRNA-based vaccine for the prevention of shingles.
  • Advised AstraZeneca on its signing of a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins.
  • Acting for Neurim on a series of disputes with Mylan (now known as Viatris) and more recently also Teva, which is currently selling a generic version of the melatonin tablet Circadin (Neurim’s only significant marketed product) in the UK.

Linklaters LLP

According to clients, Linklaters LLP stands out for its ‘extremely high quality of people, deep knowledge of the sector and ability to cover every aspect of work that is thrown its way’. The cross-practice team draws from the expertise of practitioners across the firm’s corporate, commercial, dispute resolution, IP, technology, data protection, regulatory, product liability and finance departments to provide clients with a holistic service across the full range of life sciences and healthcare work. The group’s diverse client base spans pharmaceutical, biotech, digital health and medical device companies and healthcare service providers. Aisling Zarraga and Marly Didizian co-lead the team, focusing on corporate and commercial work respectively.

Responsables de la pratique:

Aisling Zarraga; Marly Didizian

Autres avocats clés:

Alistair Fraser

Les références

‘I think what sets this team apart is the extremely high quality of their people, their deep knowledge of the sector, how commercial they are and how they can cover every aspect of work that is thrown their way. They do high end, difficult work with apparent ease, are truly fun to work with and provide a level of service I haven’t come across with other firms, and which is critical for in-house teams needing efficient and reliable support on those high-profile, strategic transactions.’

‘Marly Didizian is one of the best lawyers around in the life sciences sector, and the only one I trust to lead on the most complex and high priority deals. Her extensive healthcare and supply chain experience means she can provide advice that is innovative and commercial as well as effective. Her combination of good humour and steely negotiation on a particularly tough carve out deal not only led us to secure a very favourable outcome on this strategically important project, but also made a potentially very challenging deal process a far more positive experience for all involved.’

‘A solid offering with an understanding of what matters in the sector’

‘Marly Didizian is a stand-out partner for her knowledge of the commercial arrangements needed in the Life sciences space. Alistair Fraser is a real rising star amongst associates on the M&A/corporate side of things – great to work with!’

‘The team at Linklaters are able to field lawyers across multiple practice areas (corporate, commercial, finance, project finance, dispute resolution, IP) to provide timely advice. They are always able to field a team at very short notice, to provide insight, negotiation and drafting support in a way that materially improves the way in which legal services are perceived internally within our organisation and ultimately gives us the best opportunity to achieve the outcomes we are aiming for.’

‘Aisling Zarraga has been the cornerstone of advice for us, providing extremely responsive support on key risk issues and coordinating the team at Linklaters to be able to operate at speed, notwithstanding they may have only had periodic involvement in the project, ensuring the best practice area to support is able to do so. All in all, great client service and fun to work with.’

‘Team is always available and I feel that I can get help, even if a moral support, at any moment’

‘Marly Didizian stands out as not only a brilliant lawyer but a person with a deep commercial and even technical understanding of the project. It is rare to meet a lawyer who knows our sector as well as Marly.’

Principaux clients

Gavi, the Global Vaccines Alliance

Apax Partners

The Carlyle Group

Fresenius

PAI Partners

Hg Capital

Bayer

Nestlé

Takeda Pharmaceuticals

McKesson Corporation

Merck & Co., Inc.

Sanofi

Regeneron Pharmaceuticals

ViiV

Thermo Fisher Scientific Inc

Principaux dossiers

  • Advising Apax Partners on the €5bn sale of Unilabs.
  • Advising McKesson Corporation, a global leader in healthcare supply chain management solutions and retail pharmacy, on the sale of its UK business to Aurelius, a pan-European asset management group.
  • Successfully represented ViiV (a joint venture involving GSK) in high-profile UK patent infringement proceedings against Gilead in relation to Gilead’s HIV treatment bictegravir.

Sidley Austin LLP

With ‘unrivalled insight’ and ‘a strategic approach’, Sidley Austin LLP’s full-service life sciences practice covers the full spectrum of matters including regulatory, IP, licensing, competition, commercial and corporate mandates and leverages the firm’s network to excel at a global level. The group has recently seen notable expansion with the recruitment of the ‘tremendousRobert Darwin from Dechert LLP, adding to the team’s transactional capabilities; it is also increasingly recognised in the market for its digital health and medtech expertise, advising on matters involving AI, digital therapeutics and wearable technology. Practice head Maria Isabel Manley is praised as ‘quite simply peerless in her field’, focusing on regulatory and competition issues; she works closely with senior managing associate Chris Boyle, who is singled out as ‘an absolute superstar’.

Responsables de la pratique:

Maria Isabel Manley

Autres avocats clés:

Robert Darwin; Chris Boyle

Les références

‘In-depth knowledge of the life sciences sector as well as understanding latest market precedents for licencing and M&A situations.’

‘This is a great team. They really know the life sciences sector inside out, in addition to being great and flexible lawyers and litigators. I have worked with them on quite gruelling projects and the team at Sidley methodically pulled the task apart and found all the right points. They are first rate.’

‘Marie Manley leads the team. She is very hands on and a real fighter for her clients’ interests. She has extremely in-depth knowledge of the life sciences sector from a regulatory and patent perspective, as well as being right at the cutting edge of competition law in this area. Chris Boyle is an absolute superstar as a Senior Managing Associate. He is tremendously clever, prodigiously hard working and would be at the top of my list of people to have on any team. He also has a strong scientific background in life sciences, which is invaluable.’

‘Robert Darwin has been tremendous from a capability standpoint, working in teams, finding a solution so that the client’s interests are met and at the same time finding a solution that could make a win-win situation for everyone involved. For me he is the face of Sidley.’

‘Marie Manley is an outstanding lawyer from a technical perspective but what makes her different is the personality that she brings to her interactions with me as an in-house lawyer and my business colleagues.’

‘Unrivalled insight into the pharmaceutical and medical device regulatory framework in the EU.’

‘Marie Manley is quite simply peerless in her field. A great strategist with a deep knowledge of regulatory matters and a joy to work with. Chris Boyle is a qualified veterinarian and life-sciences lawyer who uses his scientific background to great effect when advising his clients. Great practical advice.’

‘In all the legal negotiations for in-licensing agreements with counterparties we have participated in, Robert Darwin has consistently been a strong negotiator with an inimitable and sensitive style. He is also aware of the concerns and balancing needs of multiple counterparties in a complex, structured deal.’

Principaux clients

Servier

F. Hoffman-LaRoche

Immunocore

Huma Therapeutics

KKR

Medline International

Judges Scientific Plc

Juniper Life Sciences

BeiGene

The Sylvan Group

Welsh Carson Anderson & Stowe / Managed Markets Insight & Technology, LLC

Arsenal Capital Partners and Cello Health Limited

Principaux dossiers

  • Representing Servier in three cases before the English High Court and the Supreme Court concerning parallel proceedings brought by the health authorities in England, Wales, Scotland, and Northern Ireland seeking damages for an alleged breach of competition rules in relation to Servier’s drug Perindopril.
  • Assisted Immunocore Ltd in obtaining a valuable EU orphan designation for its novel therapy, despite the fact that the regulator, the European Medicine Agency’s Committee of COMP, had refused orphan designation on two prior occasions.
  • Advised Juniper Biologics on a complex licensing and collaboration agreement with Kolon Life Sciences (Korea) in relation to TissueGene-C, a cell therapy for osteoarthritis of the knee.

Taylor Wessing LLP

Taylor Wessing LLP’s ‘combination of in-depth understanding of very complicated sciences and a way of seeing how all the moving parts of a complex agreement interweave’ makes it well placed to handle the full range of life sciences work. The practice is particularly singled out for its patent litigation expertise and also benefits from substantial experience in the firm’s Cambridge office; the team also fields specialists in regulatory issues, product liability mandates, corporate transactions and contentious matters. Regulatory expert Alison Dennis heads up the practice, which also fields IP specialists Ross McNaughton, Adrian Toutoungi and Colin McCall, and Tasmina Goraya, who handles regulatory work.

Responsables de la pratique:

Alison Dennis

Autres avocats clés:

Ross McNaughton; Adrian Toutoungi; Colin McCall; Tasmina Goraya

Les références

‘A combination of in-depth understanding of very complicated science in the Life Sciences field, and a way of seeing how all the moving parts of a complex arrangement of agreements, IP, licences and potential parties interweave. Highly responsive, pragmatic and commercial, yet thorough.’

‘The TW team how done a great job at positioning themselves as a leading life science law firm in Cambridge.’

‘Stand out partner for me has been Colin McCall, who has single-handedly helped us get a hugely complex licensing deal over the line. His understanding of the detail of licence terms and the complex background to the development of the IP was instrumental to making all the parties make appropriate concessions to getting a deal over the line, and avoiding lengthy stand offs and threats of walking away.’

Principaux clients

Abbott Laboratories

Adrestia Therapeutics

Apollo Therapeutics

Apotex

Cambridge Enterprise

Cambridge Epigenetix

Cambridge Innovation Capital

Cell and Gene Therapy Catapult

Centessa Pharmaceuticals

Colorfix

Drishti Discoveries

Exvastat

Fusion Antibodies

ImmTune Therapeutics

IP Group

JT International

Lupin Pharmaceuticals

Macomics

Mission Therapeutics

Mylan

Nuclera Nucleics

Oppilan/Zomagen

Pfizer

Reflection Therapeutics

Semarion

Spirea

Spliceor

Start Codon

TranSINE Therapeutics

Viatris

Zygosity

Principaux dossiers

  • Acting for Abbott Laboratories on co-ordinating extensive and commercially significant European patent litigation against Dexcom in respect of continuous glucose monitoring devices.
  • Advised Apollo Therapeutics, a biopharmaceutical company progressing transformative treatments based on breakthrough discoveries, on its $145m series A financing.
  • Advised fast-growing biotech company, Nuclera, on its strategic acquisition of E Ink’s digital microfluidics unit.

DAC Beachcroft LLP

DAC Beachcroft LLP is highly active in pharmaceutical and medical product liability cases and is increasingly receiving instructions involving medtech issues through its distinct medtech group. The team has been notably busy during the pandemic handling product regulatory and liability issues relating to ventilators, PPE, clinical trials, vaccines and antigen tests; the team advised NHS England on indemnity issues relating to its response to the pandemic. Alison McAdams heads up the department and excels in complex litigation.

Responsables de la pratique:

Alison McAdams

Autres avocats clés:

Charlotte Burnett

Les références

‘Sector knowledge and insights into NHS strategy and thinking.’

‘Charlotte Burnett (Partner) – excellent sector knowledge and awareness.’

Principaux clients

NHS England

NuVasive

Ipsen Pharma

Novartis

Deltex Medical

Vascutek

Optegra UK Ltd

HCA Healthcare UK

BMI Healthcare Group Limited

Poolbeg Pharma

Fieldfisher

Fieldfisher recently expanded on its traditional strength in corporate and financing transactions to handle a variety of regulatory mandates, acting for pharmaceutical, biotech and medical devices companies; the recruitment of legal director Cliodhna McDonough-Stevens into the team also adds to the team’s regulatory expertise. On the corporate front, ECM and venture capital fundraising deals have been prominent in the team’s workload. Janita Good is co-head of the international life sciences and healthcare group and leads the UK team, and Sarah Ellson in Manchester is the key regulatory expert.

Responsables de la pratique:

Janita Good

Autres avocats clés:

Cliodhna McDonough-Stevens; Sarah Ellson

Les références

‘They must be a smart firm, because they employ excellent solicitors including my solicitor who I have worked with for nearly 20 years.’

‘I can always count on getting quality advice in very honest and direct manner, which I appreciate greatly. The partner I work with is Janita Good.’

‘Fieldfisher’s broad and deep practice areas allow teams to draw on specific expertise as and when needed, offering timely and high quality advice.’

‘Sarah Ellson acts as our relationship partner. She is a pleasure to deal with, and when advising on her own area of expertise she is quick to grasp the ask and advises both succinctly but with depth of thought.’

Principaux clients

Roche Products Limited

Fresenius Kabi

KeyMed (Medical & Industrial Equipment) Limited

Synairgen plc

Inspiration Healthcare plc

Syneos Health UK

Sinclair Pharma

Tristel plc

Ultromics

Human Tissue Authority

NHS Resolution

Phoenix Healthcare/Numark

Boston House Dental Group

General Medical Council

Principaux dossiers

  • Advising Roche Products Limited on its contributions of unlicensed medicines for treatment for and help with management of the Covid-19 virus.
  • Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
  • Advised Synairgen in relation to a Phase III Clinical Trial for its interferon Beta therapeutic inhaled treatment for Covid-19.

Goodwin

Leveraging the firm’s US strength, Goodwin’s practice handles a notable volume of cross-border mandates with particular expertise in corporate and financing transactions; the group recently advised Biocon Biologics on its acquisition of Viatris’ global biosimilars business for $3bn. Graham Defries, Malcolm Bates and David Mardle jointly lead the practice; Mardle and Defries are key names for corporate and finance work and Bates excels in IP, commercial and regulatory matters. The group was also bolstered with additional IP expertise in August 2022 with the recruitment of Morag Peberdy from Covington & Burling LLP.

Responsables de la pratique:

Graham Defries; Malcolm Bates; David Mardle

Autres avocats clés:

Andrew Harrow; Tim Worden; Morag Peberdy

Les références

‘Good understanding of the sector and what matters to biotech companies. Experience in licensing agreements on a global scale.’

‘The team at Goodwin not only guided an inexperienced management through the process, but had the strength and integrity to keep asking questions and not just make assumptions that that management team would know everything going on.’

‘Andrew Harrow was an exceptional part of the process we were involved in, with a simply outstanding knowledge of detail and fantastically personable approach. In addition, his level head helped myself and the team to navigate difficult passages of the deal flow. His team were also instrumental.’

‘For me Tim Worden provides super practical and pragmatic advice that is steeped in experience and he is valued in our business.’

‘Tim Worden is a fantastic contract lawyer and negotiator. His legal skill set is top and so is his negotiation skill set. Helped us tremendously through negotiations as our lead.’

‘We have been working with the Goodwin’s team for many years. They understand our business and the way we work, and are committed to ensuring successful outcomes to negotiations.’

‘Reputation in biotech area and knowledge of the sector. Building of an experienced team. Global capabilities including US resources.’

‘Andrew Harrow- sector knowledge including benchmarks and market norms, pragmatic, good communication- straightforward and open.’

Principaux clients

Kymab

CMR Surgical

Huma Therapeutics

Centessa Pharmaceuticals Limited

Biocon Biologics

Vaccitech

Syndesi Therapeutics

Dotmatics

In4Derm

SynAffix

Sparing Vision

Oxford Biomedica

Achilles

COMPASS Pathways

Quanta Dialysis Technologies Limited

Jeito

Principaux dossiers

  • Advised Biocon Biologics on it’s acquisition of Viatris Inc’s global biosimilars business for $3.35bn.
  • Advised Achilles Therapeutics plc on its Initial Public Offering.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1bn and up to $350m upon achievement of certain milestones.

Kirkland & Ellis International LLP

Kirkland & Ellis International LLP fields a ‘great team with real depth of technical knowledge and litigation experience’. The group remains prominent in life sciences patent litigation, acting for a high-profile client roster of pharmaceutical clients including Pfizer and Novartis. The ‘clever, engaged and commercialDaniel Lim and ‘force of natureNicola Dagg lead the team’s IP litigation expertise and Emma Flett is at the helm on the transactional front. Clients also praise ‘sharp strategistJin Ooi and ‘fast thinkerKatie Coltart.

Responsables de la pratique:

Daniel Lim; Nicola Dagg; Emma Flett

Autres avocats clés:

Jin Ooi; Katie Coltart; Steven Baldwin

Les références

‘Great team with real depth of technical knowledge and litigation experience.’

‘Daniel Lim – clever, engaged and commercial. Has great technical understanding as well as litigation-sense.’

‘The Kirkland team has great strength in IP cases. Led by the highly dynamic force of nature that is Nicola Dagg, clients love them and come back regularly. You only have to the look at the cases they are in and the clients they represent to see how well regarded they are. The other partners are equally strong and the associates are hardworking and bright.’

‘Daniel Lim is excellent on technical cases. Jin Ooi has as a nose for a good point. Steve Baldwin is a great lawyer who easily gets to grips with the most complex of cases.’

‘Katie Coltart is one of the more senior partners within the team. She is very bright and has a real knack for bringing through the client’s story into the litigation.’

‘The Kirkland team has broad strength both at lower, middle and upper levels of seniority of very experienced and capable lawyers in global patent litigation. Particular strength comes from the strategic planning and analysis of multi-jurisdictional patent litigation matters, spearheaded by the senior partners and well supported by experienced and intelligent associates.’

‘Jin Ooi is great to work with. He’s extremely responsive, his attention to detail to second to none and gets the bigger picture straight away. Highly recommend for patent infringement matters’

‘Nicola Dagg and Daniel Lim have well deserved reputations as patent litigators and strategists. Nicola is rightly regarded as one of the top patent litigators in Europe. She has strong relationships with top litigators across Europe and knows the nuances of patent litigation in key jurisdictions. Daniel is our go to person for all day to day interactions. He is fully immersed in all the details as well as on top of the big picture strategy of the case. He has all the qualities of a top class litigator.’

Principaux clients

British American Tobacco (reduced risk products)

Alcon

Novartis

Regeneron Pharmaceuticals

Pfizer

Viatris

Abbott Laboratories

GSK

Meril Life Sciences

Sonova / Advanced Bionics

Patient Square Capital

Principaux dossiers

  • Representing British American Tobacco group companies in patent revocation and infringement proceedings in the UK against Philip Morris Products concerning both parties’ nicotine delivery devices.
  • Advising and representing Warner-Lambert, Pfizer, and Viatris against the NHS in relation to a follow-on damages inquiry before the Patents Court, raising novel issues of foreseeability, causation and mitigation. It will be the first damages inquiry of its kind in the UK.
  • Representing the Alcon in global patent infringement litigation against Johnson & Johnson concerning surgical laser systems for cataract surgery.

Powell Gilbert LLP

IP boutique Powell Gilbert LLP is a go-to name in the market for IP litigation and advisory work and excels in life sciences patent litigation. The team is active before the UK Patent Courts and also has experience handling matters before the Court of Appeal and the Supreme Court; it recently successfully represented Biogen in the High Court and Court of Appeal in a claim against Abbvie relating to its biosimilar Imraldi. Penny Gilbert leads the practice, which also fields highly regarded patent litigator Tim Powell.

Responsables de la pratique:

Penny Gilbert

Autres avocats clés:

Tim Powell

Principaux clients

Illumina, Inc

Edwards Lifesciences

Actavis UK Limited

Biogen Idec Inc

BioNTech

MED-EL

Otsuka Pharmaceutical Co Ltd

Royalty Pharma

NuCana plc

Oxford University Innovation

Coloplast A/S

UCB & Research Corporation Technologies

Cook Medical

Principaux dossiers

  • Representing Biogen in litigation over its biosimilar of AbbVie’s blockbuster drug Humira before the UK High Court and Court of Appeal.
  • Acting for Actavis in a claim for damages resulting from Pfizer’s unsuccessful assertion of its patent protecting the use of pregabalin for the treatment of pain.
  • Assisting BioNTech in relation to its SARS-CoV-2 vaccine, COMIRNATY.

Simmons & Simmons

At Simmons & Simmons, the healthcare and life sciences industries make up one of the firm's four focus sectors, with the firm particularly praised for its digital health expertise, where it advises on data protection issues, licensing mandates, compliance work and infrastructure arrangements. The multi-disciplinary team also has notable strength in transactional IP work and patent litigation as well as regulatory experience. Clients span pharmaceutical, medical device, biotech and gene therapy companies, healthcare operators and industry associations. Michael Gavey leads the practice and Lydia Torne focuses on IP and regulatory matters.

Responsables de la pratique:

Michael Gavey

Autres avocats clés:

Lydia Torne

Les références

‘The Simmons & Simmons team is outstanding, both as a team and the individuals forming the team. They are competent, available and have a great knowledge of our business and industry. We always consider them as our first choice when we are in need of legal support.’

‘Lydia Torne, Partner with Simmons & Simmons, is an absolutely outstanding lawyer. She acts as our trusted adviser and we entrust her with many important cases with executive management attention. She is extremely knowledgeable both within the law and our industry. She is always available to support us and her deliverables and advice are always of very high quality. She is without a doubt my top pick when I need legal support.

‘Michael Gavey is knowledgeable and pragmatic. He makes a real effort to understand our business and listen to our needs.’

‘The Simmons & Simmons team have an in-depth knowledge of the sector. On any transaction they are able to bring on board relevant experts from IP and technology to tax and corporate finance. They are commercially aware and able to suggest pragmatic solutions to close deals.’

Principaux clients

UCB

Samsung Bioepis

GSK

Infinitopes Limited

Ascendis Pharma

Insulet Corporation

Leica Biosystems & Mammotome

3M-KCI

Venture Life Group plc

Principaux dossiers

  • Advising NASDAQ listed Ascendis Pharma for over 10 years in relation to its TransCon technology.
  • Acted for Insulet in an infringement case against Roche concerning one of Insulet’s patents.
  • Advised Venture Life Group in connection with its acquisitions of two medical devices and a food supplement from Helsinn Healthcare SA for £4.7m.

Slaughter and May

Leveraging the firm’s position in the market as a transactional powerhouse, Slaughter and May’s corporate practitioners are regularly involved in high-profile corporate and financing transactions at a national and international level. In a recent highlight, the group advised GlaxoSmithKline on the demerger of its consumer healthcare business into a separately listed group. Richard Smith and Claire Jackson are the key corporate names and lead the team with Duncan Blaikie, who handles commercial work and IP issues. Transactional expert David Johnson is also recommended.

Responsables de la pratique:

Richard Smith; Duncan Blaikie; Claire Jackson

Autres avocats clés:

David Johnson

Les références

‘Committed to client objectives. Proactive and collaborative. A pleasure to work with.’

‘Duncan Blaikie – very responsive, we have valued his experience in helping us understand the longer term, commercial consequences of certain decisions and positions.

‘Great collaborative working.’

‘Expertise in the relevant market sector, including a good understanding of existing sector as well as upcoming changes. Willing to work in a way which works best for the client, with appreciation of the clients own governance processes. Providing advice outside of just legal issues, such as policy and finance.’

‘Broad knowledge base and experience.’

‘Knowledge base, experience, work ethic, willingness to go the extra mile’

Principaux clients

GlaxoSmithKline

Hikma

Thermo Fisher

Novo Nordisk

Bupa

GE Healthcare

Union Medical

Reckitt Benckiser

Immunocore

Oxford Nanopore

Lonza

CSL

Enara Bio

Artha Health Limited

International Finance Facility For Immunisation Company

Mylan

Illumina

Cantel Medical Corp

Varian Medical Systems

Afreximbank

Principaux dossiers

  • Advised The African Union on all aspects of its program to procure COVID-19 vaccines, over and above the vaccines they are securing through the COVAX Investments Limited facility.
  • Advised GlaxoSmithKline plc on the planned demerger of its Consumer Healthcare business into a separately listed group.
  • Advised Oxford Nanopore Technologies on its initial public offering on the London Stock Exchange.

Stephenson Harwood

With ‘superb knowledge of the sector’ and ‘a willingness to adapt to fit the client’s needs’, Stephenson Harwood’s practice is led by ‘absolutely brilliant solicitorAlexandra Pygall, who is an IP specialist and focuses on licensing, partnership and other commercial agreements. The practice is well regarded for its contractual commercial work and is also active in IP litigation; it recently represented GlaxoSmithKline in its trade mark and unfair competition litigation relating to the colour and shape of inhalers. Dan Holland also contributes to the group manufacturing and supply agreement expertise.

Responsables de la pratique:

Alexandra Pygall

Autres avocats clés:

Dan Holland; Jodie Lilir

Les références

‘Every single person is excellent. Superb knowledge of the sector and relevant people. Always produce a great job.’

‘Alexandra Pygall – delivers a great work product and inspires huge confidence in her team and in her clients. An absolutely brilliant solicitor. Jodie Lilir adds strength and depth to the team. A fantastic addition.’

‘The team has a strong presence in the Life Sciences sector and really understand the business of bringing new treatments successfully to the market.’

‘Alexandra Pygall has a great practice and provides strategic counsel to clients in achieving strong commercial outcomes for new therapeutic products and therapies’

‘Highly knowledgeable in relation to both law and the sector generally. Delightful to work with – efficient, reasonable, careful. Willing to adapt strategy to fit client’s needs and savvy about whether litigation is the best solution.’

‘Alexandra Pygall – there is nothing she doesn’t know about the life sciences sector and her legal skills are first rate. Jodie Lilir – fantastic attention to detail and ability to focus on the points which matter.’

Principaux clients

Acacia Pharma Group plc

AM-Pharma

Biomer

bluebird bio

BioNTech SE

BXT Accelyon

Capiton AG

Eisai Europe Ltd

e-therapeutics plc

Exscientia

GSK

Incyte Corporation

Johnson & Johnson Innovation

Novacyt

Optum Venture Global Partners, LP

Otsuka Pharmaceuticals

Oxford Biomedica plc

Schroder UK Public Private Trust plc

Shield Therapeutics Plc

UCB

Vernalis R&D

Principaux dossiers

  • Acted for GSK in the cross-border trade mark and unfair competition litigation against Sandoz in relation to the widely reported ‘purple’ litigation and ‘shape’ litigation relating to inhalers.
  • Advised AM-Pharma on its exclusive licence agreement with Kyowa Kirin for commercialisation of ilofotase alfa in Japan with an overall deal value of €245m.
  • Advised Oxford Biomedica on critical clinical and commercial supply agreements relating to the manufacture by Oxford Biomedica of third party’s products using Oxford Biomedica’s proprietary technology.

Carpmaels & Ransford LLP

Carpmaels & Ransford LLP’s ‘real strength across patent prosecution and opposition work’ benefits from the ‘highly technically qualified team’, which is ‘very collaborative and a pleasure to work with’. The group handles the full range of patent and trade mark mandates as well as advising on transactions and supplementary protection certificates (SPCs). Key individuals include managing partner Hugh Goodfellow, dispute resolution head David Wilson, IP transactional leader Jake Marshall, trade mark head Roger Lush, and James Warner and Mark Chapman, who lead the chemistry and pharmaceuticals, and biotechnology teams respectively.

Responsables de la pratique:

Hugh Goodfellow; David Wilson; Jake Marshall; Roger Lush; James Warner; Mark Chapman

Autres avocats clés:

Daniel Wise; Camilla Balleny; Richard Newell

Les références

‘C&R is unusual in having integrated teams of solicitors and patent attorneys, which enables them to provide a highly technically qualified team with a view of patent prosecution as well as litigation.’

‘We have worked closely with Jake Marshall on two complicated licensing deals over the last two years. In both occasions, Jake helped us successfully navigate through what were complicated agreements, reaching favourable terms. His knowledge of current market deal expectations was invaluable and helped greatly in delivering us the best deal.’

‘The Carpmaels team is very sophisticated and deep. They have a real strength across patent prosecution and opposition work. I use them for all my EP work and know that they will provide the highest quality work product both in terms of the legal analysis but also technical. They are creative and we consider them part of our team vs. a group that simply executes on our instructions. They are also very collaborative and a pleasure to work with.’

‘Hugh Goodfellow leads the group and is someone that we have known for many years. He did a wonderful job on a recent opposition matter that was particularly challenging — we won in large part thanks to his advocacy skills. He is also very generous in terms of promoting his partners.’

‘Carpmaels’ team members are highly educated within their technical field and can speak effectively and competently to relevant stakeholders at the company. At the agent, attorney, and solicitor level they are also very well educated with respect to the law. Both the partners and associates have depth of experience in both the technology and law, and clearly mentor more junior members of their team to provide a high level of professional rigor throughout the firm.’

‘Daniel Wise and Richard Newell are both top notch with respect to their knowledge of the chemical and biological sciences, their knowledge of the law, their personable natures, and their availability. They are honest and forthcoming with clear, targeted advice and provide detailed and thoughtful input on strategy and paths to overcoming obstacles. The team that supports them have these same traits, and work together in a very integrated and efficient fashion.’

‘The Team we work with – led by Mark Chapman – have been absolutely amazing. The depth of knowledge of legal matters combined with strength of understanding of cutting edge molecular biology is first rate.’

‘The team with whom we work is smart and true thought partners. When they bring issues to us, they begin with the recommendation, but then take a step back to show how they got there and what additional angles they evaluated. There is no stone left unturned.’

Principaux clients

Regeneron Pharmaceuticals, Inc.

Incyte

Biogen Inc.

Johnson & Johnson Vision

Align Technology

Novartis

Vertex

Gilead

Johnson & Johnson, with Boston Scientific

Jazz Pharmaceuticals

CSL

LifeScan, Inc.

Ethicon Inc. & Ethicon LLC

McNeil AB

Acorda Therapeutics

Biosense Webster

Abbott Laboratories

Raytheon Technologies Corporation

Janssen Pharmaceuticals

LEO Pharma

Afiniti, Ltd.

Auris Health / Verb Surgical

Quantum – Si

Amgen

Principaux dossiers

  • Achieving an important victory for FibroGen, Inc., in which the Court of Appeal found that FibroGen’s patents were in fact valid on the ground of sufficiency, a decision with wider legal relevance.
  • Representing Johnson & Johnson subsidiary, AMO Development, LLC, in a multi patent revocation and infringement action commenced by Alcon in relation to AMO’s technology for laser eye surgery machinery.
  • Defending Bristol Myers Squibb’s patent estate covering its blockbuster product Revlimid.

DLA Piper

The life sciences practice at DLA Piper is active in corporate, commercial and financing transactions, acting for a high-profile client roster including Pfizer, Unilever and Takeda. The team also recently launched its cannabis and psychedelic medicines practice, led by senior associate Dylan Kennett. Richard Taylor leads the wider department from Birmingham and advises on IP, technology and commercial law.

Responsables de la pratique:

Richard Taylor

Autres avocats clés:

Dylan Kennett

Principaux clients

Pfizer Inc

Unilever PLC

Takeda

Department of Health and Social Care

Joint Administrators of NMC Health PLC

Clinigen Plc

Velindre NHS Trust

Avicanna

Otsuka Pharmaceutical Development and Commercialization Inc

Medica Group plc

Advanced Medical Solutions Group plc

Phytome Life Sciences Limited

Laerdal Medical AS

Incyte Corporation

Altmed Pets LLC (trading as Pet Releaf)

Philip Morris International

Guerbet SA

HutchMed (China) Limited

Anthony Nolan Trust

NHS Digital

Leafy Tunnel

Aurelius Investments Limited

Alvarez & Marsal

Sciontec Developments Limited

LCR Ventures Limited

Principaux dossiers

  • Advising Philip Morris International on the acquisition Fertin Pharma A/S, a leading developer and manufacturer of pharmaceutical and well-being products based on oral and intra-oral delivery systems.
  • Advising Guerbet on the drafting and negotiating of its contracts with its competitor Bracco for joint exploitation of Gadipiclenol, a ground-breaking and novel contrast agent used in diagnostic imaging.
  • Advising global biopharmaceutical company HUTCHMED on its Hong Kong public offering.

Hill Dickinson LLP

Hill Dickinson LLP’s team handles the full spectrum of life sciences and healthcare mandates from corporate and commercial matters to regulatory issues and litigation. The practice also has various areas of niche expertise including extensive knowledge of the medical cannabis sector and issues relating to fertility including IVF and embryo research, and is growing its biotech and healthtech knowledge. Litigation and regulatory expert James Lawford Davies, commercial specialist Jamie Foster and Michael Corcoran, who is active in the alternative proteins sector, jointly lead the team.

Responsables de la pratique:

James Lawford Davies; Jamie Foster; Michael Corcoran

Autres avocats clés:

Richard Parker

Les références

‘Approachable, responsive, competent but very straightforward and transparent. We are a fast growing SME and Hill Dickinson has acted as a real partner for us.’

‘Jamie Foster and Richard Parker have both been excellent.’

‘Very approachable and always offer individualised service.’

‘The partner we deal with – Michael Corcoran – goes way beyond expected to deliver innovative solutions to problems. His attention to detail is outstanding and continues to impress with his breadth of knowledge.’

‘The HD Healthcare team is broadly knowledgeable of the fertility industry and a perfect partner to advise companies in the field.’

‘James Lawford-Davies has been our partner for several years. He is the go-to expert in all things reproductive in the UK. In addition to his legal expertise, he is well versed in the field of fertility and the business of fertility.’

Principaux clients

Touchpoint Medical

Dr. Schär UK

Genflow Biosciences

Agronomics

The Royal Marsden NHS Foundation Trust

Rinicare

KSS AHSN/Unity Insight

The Royal Wolverhampton NHS Trust

Babylon Health

Yooma Wellness Inc

PAM Occupational Health Solutions Limited

Hilltop Leaf

Fishawack Health

EMMAC Life Sciences

Medicines Discovery Catapult Ltd

Centre for Process Innovation (“CPI”)

ADDVantage Technologies

Assisted Reproduction and Gynaecology Centre

Juvenescence Ltd

The Fertility Partnership Ltd

California Cryobank

Insilico Medicines, Inc

Agronomics Limited

iOx Therapeutics Ltd

JD Healthcare

Lyphe Group

CME Medical Ltd

OBG Pharmaceuticals Ltd

Genus Plc

Push Dr Ltd

Life Sciences Developments Ltd

ARGC Ltd

Create Health Ltd

SalvaRx Group Plc

Sinclair Pharma Plc

Port Erin Biopharma Investments

SmartMed Global

Napa Therapeutics Ltd

Sativa Investments PLC

FastForward Innovations Ltd

Thermo Electron (Management) Services Ltd

Sativa Group PLC

Medicines Discovery Catapult Ltd

GoodSAM

Reproductive Health Group

Centre for Process Innovation

IVCC (Innovative Vector Control Consortium)

Sapphire Medial Clinics

TMRW

The Fertility Partnership

London Women’s Clinic

Principaux dossiers

  • Advised EMMAC Life Sciences Limited (EMMAC), Europe’s largest independent vertically integrated medical cannabis company, on it’s sale to CureLeaf Holdings, deal value was $345m.
  • Acted for Genflow on a £3.7m oversubscribed placing and the company’s admission to the standard segment of the main market of the London Stock Exchange.
  • Advised The Royal Marsden NHS Foundation Trust on a US partnership with Guardant Health to improve patient access to personalised cancer treatment.

Latham & Watkins

Sitting within the firm’s global practice, the healthcare and life sciences team at Latham & Watkins is a key name for corporate and commercial work, handling M&A transactions, carve-outs, private equity matters, venture capital deals and commercial agreements. Corporate group co-chair Robbie McLaren is also global co-chair of the healthcare and life sciences industry group.

Responsables de la pratique:

Robbie McLaren

Principaux clients

Abcam

Abbvie

Acino Pharma

Amgen

Astellas Pharma

Atai

Atnahs Pharma

Baxter

BenevolentAI

BC Partners

Collplant

Cooper Comapanies

CVC Capital Partners

Eleusis

Exscientia

GlaxoSmithKline

KKR

Ligand Pharmaceuticals

Meira GTx

Mereo BioPharma

Nordic Capital

Norgine

Novartis

Novo Holdings

Oasmia

Osler Diagnostics

Permira

Pharmanovia

Pharmaseeds

Pharmathen

Silverlake Partners

Sobi

Synthon

Theramex

Zogenix

Principaux dossiers

  • Advised Novartis, a global healthcare company, on its acquisition of Gyroscope Therapeutics, an ocular gene therapy company with a late-stage clinical trial product candidate designed to treat geographic atrophy, a disease for which there are currently no approved therapies.
  • Advised Advised BenevolentAI, a leading clinical-stage AI drug discovery company, on its definitive agreement for a business combination with Odyssey Acquisition S.A., a Euronext Amsterdam-listed special purpose acquisition company.
  • Advised GRAIL, a company focused on multi-cancer early detection, on its $8bn sale to Illumina, a company focused on large-scale analysis of genetic variations and functions.

McDermott Will & Emery UK LLP

McDermott Will & Emery UK LLP’s team of ‘innovators who think outside the box’ is led by transactional specialist Sharon Lamb, whose ‘knowledge of the sector and commercial awareness is unparalleled’. The group’s client roster spans global pharmaceuticals, biotech start-ups and businesses at the intersection of healthcare and technology. The practice excels in the corporate arena, handling M&A transactions at a national and international level. UK office managing partner Hamid Yunis also contributes to the team and associate David Gibson has experience in proton beam therapy and radiotherapy projects.

Responsables de la pratique:

Sharon Lamb

Autres avocats clés:

Hamid Yunis; David Gibson

Les références

‘Extensive experience across the private health sector. Innovative approach to negotiation and litigation.’

‘Sharon Lamb – bright, determined, leaves no stone unturned on behalf of her clients.’

‘The team is extremely knowledgeable about the sector.’

‘Sharon Lamb’s knowledge of the sector, and commercial awareness, is unparalleled.’

‘Strong healthcare team with access to MDE US clients. Innovative thinkers who think outside the box.’

‘Hamid Yunis leads the team and has an impressive range of knowledge. He has a reassuring client manner and knows his stuff.’

‘A very can do firm, always seeking to find solutions rather than problems.’

‘David Gibson and Hamid Yunis have both been very professional and are quick responders and go the extra mile. Sage advice and clear guidance, often working long hours to deliver.’

Principaux clients

Antion Biosciences SA

Apposite Capital LLP

Clermont Group

Cleveland Clinic

Elite Body Sculpture

Invitae Corporation

Nanomerics Limited

PharmaLex Group and Auctus Capital Partners AG

Specsavers

WEP Clinical

Principaux dossiers

  • Represented PharmaLex Group and Auctus Capital Partners AG on their leveraged acquisition of Phlexglobal from international private equity sponsor, Vitruvian Partners.
  • Advised Nanomerics Limited on its expansion and renegotiation of commercial terms in its license and collaboration agreement with Virpax Inc for anti-viral AnQlar, providing Virpax with the worldwide rights for development and commercialisation.
  • Representing Cleveland Clinic in connection with its opening of Cleveland Clinic London Hospital, a 184-bed hospital.

Mills & Reeve LLP

Mills & Reeve LLP is praised by clients for its ability to ‘apply its expertise in a concise and pragmatic manner’ with practice head James Fry providing ‘agile and reliable advice’ to the firm’s client roster of global pharmaceutical businesses, start-ups, universities, research institutes and government organisations. While the firm handles a varied mix of work, it is particularly noted for its experience in research collaborations and in and out licensing transactions.

Responsables de la pratique:

James Fry

Les références

‘The application of their expertise in a concise and pragmatic manner sets then apart from similar firms. They understand our business needs and are always on hand as a virtual extension of our in-house team.’

‘James Fry leads an excellent team. His experience and understanding of the challenges that small biotechs face results in agile and reliable advice.’

‘Excellent employment team. Practical, timely, reasonably-priced advice.’

Principaux clients

F-star Therapeutics

GlaxoSmithKline

The Binding Site

Mission Therapeutics

Autolus Limited

Kadans Science Partners

Diurnal Group

Charnwood Molecular Limited

Sphere Fluidics

Redx Pharma

Principaux dossiers

  • Acted for long standing client, F-star Therapeutics, on its licence and collaboration agreement with Janssen Biotech, Inc.
  • Advised Kadans Science Partner in relation to the acquisition of 5-10 Brandon Road, Kings Cross, London.
  • Advised NASDAQ listed Artisan Acquisition Corp on its merger with Prenetics, a global leader in genomic and diagnostic testing.

Mishcon de Reya LLP

At Mishcon de Reya LLP, the life sciences team recently expanded its patent litigation expertise with the recruitment of Campbell Forsyth, who has ‘a careful and intelligent approach to patent litigation’. Beyond patent work, the practice is active across the pharmaceutical, medical device, biotech, agrochemical and veterinary medicine fields with particular expertise in clinical trial work and commercial matters. Martyn Hann heads up the group and regularly handles development agreements.

Responsables de la pratique:

Martyn Hann

Autres avocats clés:

Campbell Forsyth

Les références

‘Mishcon de Reya has recently recruited Campbell Forsyth to bolster their patent experience. Campbell is an experienced practitioner will a careful and intelligent approach to patent litigation. He is particularly adept at reading what the client wants, even if they don’t know it themselves yet, and identifying the best ways to deliver it.’

‘A diverse and very professional team, with a breadth of experience across the IP field.’

‘Campbell Forsyth is widely regarded for his experience in international patent litigation in pharmaceutical/biopharmaceutical fields. Very bright and on top of all the details, he pushes matters forwards in a strategic and highly commercial manner.’

‘Great team with a great diversity, excellent collaboration and responsiveness. it is a pleasure working with them. They also have an innovative way of working which guarantees to get value for money.’

‘My primary contact throughout the years has been Martyn Hann. I can describe my experience working with Martyn only in superlative terms. Martyn has shown great competencies on many different topics and in many different aspects, pragmatic spirit and a great solution oriented attitude.’

Principaux clients

Dr Reddy Laboratories

Lupin Limited

Zentiva

Perrigo Group

O’Brien Group

Oncobayes Limited

United Bioscience Corp (UBC)

UPL Europe Limited

Principaux dossiers

  • Representing DRL in a significant damages inquiry against Warner-Lambert in relation to its second medical use patent relating to pregabalin.
  • Representing Zentiva in defending a significant pharmaceutical case brought by Novartis concerning its patent application relating to its product Gilenya.
  • Advising UBC (United Bioscience Corp) on its CRO activity in the management of clinical trials for a number of Pharma companies.

Morgan, Lewis & Bockius UK LLP

Morgan, Lewis & Bockius UK LLP’s ‘excellent reputation in the UK’ attracts a broad range of work encompassing transactional mandates, regulatory issues, employment work and competition matters. Tim Corbett heads up the group; he specialises in advising early-stage biotech companies on capital raisings and also regularly acts for venture capital investors. Frances Murphy is the key contact for competition work and Louise Skinner focuses on life sciences-related employment matters.

Responsables de la pratique:

Tim Corbett

Autres avocats clés:

Frances Murphy; Louise Skinner; Paul Ranson

Les références

‘This legal firm has an excellent reputation in the UK, particularly in supporting life sciences, health care, pharmaceuticals and medical devices. Partners and associates demonstrate a high level of competency, expertise and knowledge in this sector. Work is always completed on time and to a very high standard.’

‘Paul Ranson is an exceptional legal mind in the healthcare sector. He is a great all rounder with extensive knowledge and expertise in all areas. Paul is extremely strong in pharmaceuticals and medical devices. He has a great reputation for delivering work of the highest standard in a timely manner. Paul is a great communicator and is able to explain complex legal matters in a simple and understandable way.’

Principaux clients

uniQure

Calibre Scientific

Advanz Pharma (ex Concordia Inc.)

Focus Pharma

AMCo Pharma

AstraZeneca UK Limited

Novartis Pharmaceuticals

Principaux dossiers

  • Advised uniQure N.V., a leading gene therapy company, on its agreement to acquire Corlieve Therapeutics, a private French biotech company.
  • Advised Calibre Scientific, a portfolio company of international private equity firm StoneCalibre, on the acquisition of 100% of Reagecon Diagnostics Ltd.
  • Leading Concordia’s/Advanz’s defence in relation to the alleged excessive and unfair pricing of the thyroid drug Liothyronine under Chapter II / Article 102.

Ropes & Gray

Ropes & Gray continues to benefit from the 2021 recruitment of practice head Lincoln Tsang, who adds considerable regulatory expertise to the firm’s global team and leads the European life sciences practice. The group is active in advising pharmaceutical and medical device companies on regulatory compliance and market access issues regarding UK, EU and cross-border work. Other key areas of expertise include advising on research and development strategies, product acquisitions, risk management work and investigations.

Responsables de la pratique:

Lincoln Tsang

Les références

‘Lincoln Tsang has been my company’s European consultant for many years and has helped us navigate the European landscape. This individual is very attentive and comes with great recommendations/strategy. He is always willing to help review documents and provide constructive comments to make sure we have made the strongest argument in our regulatory documents. We are a smaller company but Lincoln provides us with the same level of attention as would be seen if we were a larger organisation.’

‘Lincoln Tsang is an exceptionally experienced life sciences lawyer. He has a deep knowledge of his subject matter area and is able to provide thoughtful, timely and pragmatic advice. His availability and engagement, whether are small or large project is exceptional.’

‘Knowledgeable about life sciences practice in Europe. Great network of life science law firms globally. Team is highly responsive, and goes the extra mile to service clients.’

‘We work closely with Lincoln Tsang in the UK office. He is a trusted adviser to our company, and has become an integral part of the team as it relates to understanding and executing on our regulatory strategy in Europe. He is knowledgeable and a subject matter expert in the area of life sciences law in Europe, highly collaborative and a great partner to work with.’

Principaux clients

Orphalan (previously Gmp-Orphan)

Intrabio

Nasus Pharma

Merck KGaA

Horizon Therapeutics

Bain Capital

Neogenomics

bluebird

Ipsen Biopharmaceuticals

BioMarin

Spruce Biosciences

Gyroscope Biotherapeutics

Mirum Pharmaceuticals

Avista Capital Partners

Blackstone Group

Novavax

Pfizer

PTC Therapeutics

Takeda Pharmaceuticals International

Principaux dossiers

  • Advised NeoGenomics, Inc. on its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, UK.
  • Advised leading health care investors Avista Capital Partners and Nordic Capital and Swiss pharmaceutical company Acino on the sale of Acino to ADQ, one of the Middle East’s largest holding companies.
  • Advised Singapore’s sovereign wealth fund, GIC, on its acquisition of a 40% interest in The Oxford Science Park from Magdalen College, Oxford.

RPC

RPC’s life sciences practice leverages the firm’s insurance strength to assist clients with high-profile and complex product liability issues, particularly relating to medical devices. Dorothy Flower leads the practice and is noted for her expertise in the defending manufacturers and suppliers in medical device and pharmaceutical product liability claims. The group also has experience in clinical trial work, regulatory issues, inquests and group litigation.

Responsables de la pratique:

Dorothy Flower

Les références

‘The experienced RPC team acts for a range of life sciences and healthcare providers and their insurers. The firm impresses with expertise across the whole range of work from the intellectual property aspects to clinical trials, inquests and product safety.’

‘Dorothy Flower leads the team with skill and determination. She has excellent sector knowledge as well as an impressive strategic and tactical approach. Her product liability and clinical negligence experience dovetails well with her life sciences practice and she is particularly strong on the issues arising from clinical trials.’

Principaux clients

Make Yourself Amazing (MYA)

Corin Ltd

Nagor Limited

GR Lane Health Products Limited

Everlight

Principaux dossiers

  • Acting for Corin Limited in defending claims concerning Metal-on-Metal hips in Scotland, Germany and Canada.
  • Acting for Insurers of a clinical trial, in relation to a claim by a trial subject who alleges complex adverse consequences following his participation.

Squire Patton Boggs

Squire Patton Boggs’ ‘strong sense of commercialism and client-focused solutions based on a deep understanding of the sector’ allows the life sciences practice to excel in the pharmaceutical and medical device sectors, primarily focusing on regulatory and commercial issues. The group also regularly advises on product clearance, advertising and promotional matters, and the distinct healthcare team provides a range of advice to healthcare organisations. Commercial and IP specialist Andrew Wilkinson and healthcare experts Diarmuid Ryan and Mark Yeo jointly lead the group.

Responsables de la pratique:

Andrew Wilkinson; Diarmuid Ryan; Mark Yeo

Autres avocats clés:

Adrian Spooner

Les références

‘The combination of deep subject knowledge of the sector (spanning pharmacy/pharmaceutical industry/health policy/government & NHS insights) is in my experience unique.’

‘Adrian Spooner is an outstanding practitioner. His advice is always implementable in a practical way through business operations. I believe this is due to his legal knowledge & experience being added to by being a pharmacist and direct experience from the pharmaceutical industry.’

‘A strong sense of commercialism and client focused solutions based a deep understanding of the sector.’

Stevens & Bolton LLP

Stevens & Bolton LLP’s ‘very proactive and responsive’ team is a key contact for pharmaceutical companies, biotech businesses, digital health providers, medical device manufacturers and sector trade bodies. The practice has been notably active advising on the implementation of the Falsified Medicines Directive and issues arising from the Covid-19 pandemic; it is also experienced in medicine supply chain issues, M&A and commercial work. IP expert Charlotte Tillett leads the Guildford-based group, which also includes risk management specialist Michael Frisby and competition expert Gustaf Duhs.

Responsables de la pratique:

Charlotte Tillett

Autres avocats clés:

Michael Frisby; Gustaf Duhs

Les références

‘Stevens & Bolton offered our business a wide range of commercial, constitutional and public law legal advice. The company brought in the right skills and capabilities to work together to provide solid legal advice that enabled the board of directors to make the right decisions to maintain the viable commercial status of the company.’

‘Gustaf Duhs has provided insightful legal advice on a range of constitutional and public law issues that has enabled our company to meet its objectives. Michael Frisby has been very helpful in helping us understand how to tackle performance issues commercially with one of our suppliers.’

‘Very proactive and responsive. Knowledgeable about the sector. Easy to work with and good value for money.’

‘Charlotte Tillett and Michael Frisby are stand out names.’

Principaux clients

Accord Healthcare

BIAL – Portela & Ca S.A

Blatchford Ltd (formerly Chas A Blatchford & Sons Ltd)

BOC Group (Part of the Linde Group)

Brain Biotechnology Research and Information Network AG

British Generics Manufacturers Association

Drugs for Neglected Diseases initiative (DNDi)

Glenmark Pharmaceutical Europe Ltd

Insud Pharma

inVentiv Health

Lonza Biologics Plc

Octopus Healthcare

Philips Healthcare

Sciensus

SecurMed UK

The Institute of Cancer Research

Principaux dossiers

  • Supporting a global biotechnology company in relation to IP licensing, including negotiating complex cross-border patent and knowhow licence agreements with major pharmaceutical companies.
  • Assisting a leading digital health provider with complex regulatory, data privacy and commercial issues in relation to its establishment in the UK, including telemedicine aspects and product safety authorisations.
  • Advising an international biotech company on a payment and trade secrets dispute concerning a patent and knowhow licence agreement.